A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma Previously Treated With Brentuximab or Checkpoint Inhibitors
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 04 May 2022 Status changed from not yet recruiting to recruiting.
- 14 Mar 2022 Planned initiation date changed from 31 Jan 2022 to 30 Jun 2022.
- 14 Dec 2021 Planned initiation date changed from 15 Nov 2021 to 31 Jan 2022.